Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer
.
Source: OncoImmunology - Category: Cancer & Oncology Authors: Dhifaf Sarhan Caroline Leijonhufvud Shannon Murray Kristina Witt Christina Seitz Majken Wallerius Hanjing Xie Anders Ull én Ulrika Harmenberg Elisabet Lidbrink Charlotte Rolny John Andersson Andreas Lundqvist Source Type: research